The short history behind the first mRNA vaccines against COVID

[ionelv]

mRNA vaccine history:
https://www.statnews.com/2020/11/10/the-story-of-mrna-how-a-once-dismissed-idea-became-a-leading-technology-in-the-covid-vaccine-race/
https://publichealth.jhu.edu/2021/the-long-history-of-mrna-vaccines
https://cihr-irsc.gc.ca/e/52424.html

Safety:
https://www.universityofcalifornia.edu/news/covid-vaccine-came-out-super-quickly-heres-why-its-safe

Stage 3 trials:
https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-conclude-phase-3-study-covid-19-vaccine

Short COVID vaccine history in Romanian:
https://commission.europa.eu/strategy-and-policy/coronavirus-response/safe-covid-19-vaccines-europeans/how-are-vaccines-developed-authorised-and-put-market_ro

Similarities and dissimilarities between COVID-19 virus and previous corona viruses:
https://www.annualreviews.org/content/journals/10.1146/annurev-micro-110520-023212

mRNA vaccine technology:
https://www.nature.com/articles/nrd.2017.243
https://www.nature.com/articles/s41573-021-00283-5
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10384963/
https://jbiomedsci.biomedcentral.com/articles/10.1186/s12929-023-00977-5

Pharmacovigilance:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9589581/
https://www.mdpi.com/1424-8247/17/6/807
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8662238/
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10043970/

Misinformation:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9858741/

GBS and COVID vaccines:
https://www.jwatch.org/na56706/2023/11/20/covid-19-and-vaccines-risk-factors-guillain-barr-syndrome
"[...] cohort of 3,193,951 patients [...] 76 patients diagnosed with GBS [...] Adenovirus-vectored vaccines showed a 2.4 times increased risk of GBS that was about seven times higher compared with mRNA-based vaccines."

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10896967
"We included 17 cohorts from 13 studies, collecting 1450 GBS cases over a total of 1,058,927,070 administered vaccine doses. The random-effects model yielded 1.25 GBS cases per million vaccine doses (95%CI 0.21; 2.83). [...] The GBS rate for adenovirus-vectored vaccines was five times higher than for mRNA vaccines."